Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtTEnd trial of atezolizumab plus carboplatin + paclitaxel in advanced or recurrent endometrial cancer
jRCT2031190013Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) and endometrial carcinosarcoma comparing Atezolizumab arm with Placebo control arm (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Sep 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on jRCT2031190013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190013.